- Home
- ACHV vs RLMD Comparison
ACHV vs RLMD Comparison
Compare ACHV & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACHV
- RLMD
- Stock Information
- Founded
- ACHV N/A
- RLMD 2004
- Country
- ACHV Canada
- RLMD United States
- Employees
- ACHV N/A
- RLMD N/A
- Industry
- ACHV Biotechnology: In Vitro & In Vivo Diagnostic Substances
- RLMD Biotechnology: Pharmaceutical Preparations
- Sector
- ACHV Health Care
- RLMD Health Care
- Exchange
- ACHV Nasdaq
- RLMD Nasdaq
- Market Cap
- ACHV 137.6M
- RLMD 110.6M
- IPO Year
- ACHV N/A
- RLMD N/A
- Fundamental
- Price
- ACHV $3.69
- RLMD $0.36
- Analyst Decision
- ACHV Strong Buy
- RLMD Hold
- Analyst Count
- ACHV 5
- RLMD 4
- Target Price
- ACHV $14.80
- RLMD $4.25
- AVG Volume (30 Days)
- ACHV 142.3K
- RLMD 2.1M
- Earning Date
- ACHV 11-07-2024
- RLMD 11-07-2024
- Dividend Yield
- ACHV N/A
- RLMD N/A
- EPS Growth
- ACHV N/A
- RLMD N/A
- EPS
- ACHV N/A
- RLMD N/A
- Revenue
- ACHV N/A
- RLMD N/A
- Revenue This Year
- ACHV N/A
- RLMD N/A
- Revenue Next Year
- ACHV N/A
- RLMD N/A
- P/E Ratio
- ACHV N/A
- RLMD N/A
- Revenue Growth
- ACHV N/A
- RLMD N/A
- 52 Week Low
- ACHV $3.41
- RLMD $0.34
- 52 Week High
- ACHV $5.59
- RLMD $7.22
- Technical
- Relative Strength Index (RSI)
- ACHV 26.02
- RLMD 17.00
- Support Level
- ACHV $4.07
- RLMD $0.34
- Resistance Level
- ACHV $4.21
- RLMD $0.40
- Average True Range (ATR)
- ACHV 0.22
- RLMD 0.09
- MACD
- ACHV -0.06
- RLMD -0.02
- Stochastic Oscillator
- ACHV 8.49
- RLMD 0.72
About ACHV Achieve Life Sciences Inc.
Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for niceon.
About RLMD Relmada Therapeutics Inc.
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its lead product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.